Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed Form 6-K on October 16, 2024. The filing announces the commencement of patient screening and recruitment for a Phase 2 clinical trial of its candidate drug, OK-101, intended to treat Neuropathic Cystitis (NCP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and contains no financial statements or quantitative financial data.
Material Changes
The primary material change reported is the operational milestone of initiating the Phase 2 trial for OK-101. No financial changes versus prior periods are disclosed in this document.
Outlook, Risks, and Management Commentary
- Clinical Trial Design: The study is a double-masked, randomized, 12-week placebo-controlled trial.
- Enrollment Target: A total of 48 patients are planned for enrollment, with NCP disease confirmed via confocal microscopy.
- Primary Endpoint: The study aims to measure pain relief using the Visual Analog Scale (VAS).
- Legal Disclaimer: The announcement is furnished as Exhibit 99.1 and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the enrollment progress and timeline for the 48-patient Phase 2 trial.
- Monitor future filings for financial updates, as this 6-K contains no financial data.
- Track the results of the primary endpoint (VAS pain relief) upon trial completion.
- Confirm the regulatory status of OK-101 in subsequent reports.